Pfizer Investor Presentation — October 2019

Document content

Earnings Teleconference

Senior Vice President, Investor Relations 3Forward -Looking Statements and Non- GAAP Financial Information

Our discussions during this conference call will include forward -looking statements about, among other things, our anticipated future operating and

financial performance, expectations for our product pipeline, in -line products and product candidates, including anticipated regulatory submissions,

data read -outs, study starts, approvals, revenue contribution, growth performance, timing of exclusivity and potential benefits, strategic reviews,

capital allocation objectives, business -development plans, the benefits anticipated from the reorganization of our commercial op erations in 2019,

plans and prospects of our acquisitions and other business development activities, including our proposed transaction with My lanN.V. (Mylan) to

combine Upjohn and Mylan to create a new global pharmaceutical company, our acquisition of Array BioPharma Inc. and our trans action with GSK

which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to suc cessfully

capitalize on growth opportunities and prospects, manufacturing and product supply and plans relating to share repurchases and d ividends that

are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such

statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10 -K for the fiscal ye ar ended

December 31, 2018 and in our subsequent reports on Form 10 -Q, including in the sections thereof captioned “Risk Factors” and “Forward -Looking

Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S.